Pharmacology articles

TCT 2022

TCT 2022 | PCSK9 Inhibitor in Patients with STEMI to Lower LDL Cholesterol

TCT 2022 | PCSK9 Inhibitor in Patients with STEMI to Lower LDL Cholesterol

In patients with ST-elevation myocardial infarction (STEMI), early treatment with statins —regardless of low-density lipoprotein (LDL) cholesterol levels — is routine around the world. Adding a potent LDL lowering agent, as a PCSK9 inhibitor, has proven clinical benefits in patients with a history of acute coronary syndrome or atherosclerosis, since treatment with statins have not

Top